Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (7634)	11/3/1998 5:22:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Bluegreen, your post was addressed to anyone who knows, so I do not qualify as one who can answer. But this has never stopped any other poster. Yes, I think a recommendation for an early halt will be seen as bullish and as improving the chances for approval. The lack of an early halt will be seen the opposite way. I thought the meeting would come very near the end of the trial. Think M.M. has even said Jan. while I thought mid Dec. was the probable time of the meeting. In any event people should factor into their decisions that the meeting of the DSMB will be of importance to the price of the stock. The only problem is we don't know what they will recommend. And in addition the lack of an early halt does not mean absolutely that Neuprex will not be approved. Many drugs that are approved have gone through their entire trial protocol without an early halt. Does any one have statistics on the number of drugs that had DSMB early halt recommendations and then were approved? Or on # of trials that run full course and result in approval?